Merryl Cramer

1.2k total citations · 1 hit paper
16 papers, 846 citations indexed

About

Merryl Cramer is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Genetics. According to data from OpenAlex, Merryl Cramer has authored 16 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 3 papers in Genetics. Recurrent topics in Merryl Cramer's work include Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (4 papers) and Genetics and Neurodevelopmental Disorders (3 papers). Merryl Cramer is often cited by papers focused on Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (4 papers) and Genetics and Neurodevelopmental Disorders (3 papers). Merryl Cramer collaborates with scholars based in United States. Merryl Cramer's co-authors include Michael F. Gardner, Joyce James, Shripad S. Bhagwat, Hitesh Patel, Qi Chao, Ruwanthi N. Gunawardane, Patrick P. Zarrinkar, Kelly G. Sprankle, Robert C. Armstrong and Keith W. Pratz and has published in prestigious journals such as Blood, Journal of Medicinal Chemistry and Drug Metabolism and Disposition.

In The Last Decade

Merryl Cramer

16 papers receiving 828 citations

Hit Papers

AC220 is a uniquely potent and selective inhibitor of FLT... 2009 2026 2014 2020 2009 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    2009 474 citations Patrick P. Zarrinkar, Ruwanthi N. Gunawardane et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Merryl Cramer United States 11 451 437 215 153 118 16 846
Dong-Mei Feng United States 15 223 0.5× 330 0.8× 168 0.8× 119 0.8× 79 0.7× 18 773
Erica O’Bryan United States 7 192 0.4× 709 1.6× 115 0.5× 30 0.2× 210 1.8× 8 930
Itsuro Shimada Japan 10 161 0.4× 194 0.4× 65 0.3× 132 0.9× 39 0.3× 19 490
Jack A. Kauffman United States 16 122 0.3× 416 1.0× 73 0.3× 365 2.4× 49 0.4× 30 853
Agustin O. Pineda United States 13 346 0.8× 289 0.7× 103 0.5× 51 0.3× 26 0.2× 16 644
Christine Lambert‐van der Brempt United Kingdom 11 81 0.2× 520 1.2× 63 0.3× 331 2.2× 78 0.7× 20 925
Gerard Costello United Kingdom 12 84 0.2× 526 1.2× 47 0.2× 314 2.1× 147 1.2× 16 946
Rohan Mendonca United States 8 130 0.3× 360 0.8× 316 1.5× 159 1.0× 10 0.1× 8 717
Christophe Thurieau France 16 75 0.2× 346 0.8× 122 0.6× 103 0.7× 46 0.4× 28 625
Da-Sheng Wang United States 12 112 0.2× 696 1.6× 195 0.9× 68 0.4× 33 0.3× 13 1.1k

Countries citing papers authored by Merryl Cramer

Since Specialization
Citations

This map shows the geographic impact of Merryl Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merryl Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merryl Cramer more than expected).

Fields of papers citing papers by Merryl Cramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merryl Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merryl Cramer. The network helps show where Merryl Cramer may publish in the future.

Co-authorship network of co-authors of Merryl Cramer

This figure shows the co-authorship network connecting the top 25 collaborators of Merryl Cramer. A scholar is included among the top collaborators of Merryl Cramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Merryl Cramer. Merryl Cramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Abraham, Sunny, Michael J. Hadd, Lan P. Tran, et al.. (2011). Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(18). 5296–5300. 13 indexed citations
2.
3.
Zarrinkar, Patrick P., Ruwanthi N. Gunawardane, Merryl Cramer, et al.. (2009). AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 114(14). 2984–2992. 474 indexed citations breakdown →
4.
Tehrani, Lida, Nicholas D. Smith, Dehua Huang, et al.. (2005). 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15(22). 5061–5064. 10 indexed citations
5.
Venkatraman, Shankar, Jongwon Lim, Merryl Cramer, et al.. (2005). Influence of acid surrogates toward potency of VLA-4 antagonist. Bioorganic & Medicinal Chemistry Letters. 15(18). 4053–4056. 6 indexed citations
6.
Chua, Peter, Johnny Nagasawa, Leo Bleicher, et al.. (2005). Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15(20). 4589–4593. 11 indexed citations
7.
Smith, Nicholas D., Thomas S. Reger, Joseph E. Payne, et al.. (2005). Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia. Bioorganic & Medicinal Chemistry Letters. 15(13). 3197–3200. 3 indexed citations
8.
James, Joyce K., et al.. (2005). METABOLISM AND DISPOSITION OF A POTENT GROUP II METABOTROPIC GLUTAMATE RECEPTOR AGONIST, IN RATS, DOGS, AND MONKEYS. Drug Metabolism and Disposition. 33(9). 1373–1381. 4 indexed citations
9.
Bonnefous, Céline, Jean‐Michel Vernier, John H. Hutchinson, et al.. (2005). Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorganic & Medicinal Chemistry Letters. 15(19). 4354–4358. 36 indexed citations
10.
Green, Mitchell D., Xiaoqing Yang, Merryl Cramer, & Christopher D. King. (2005). In vitro metabolic studies on the selective metabotropic glutamate receptor sub-type 5 (mGluR5) antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]-pyridine (MTEP). Neuroscience Letters. 391(3). 91–95. 10 indexed citations
11.
12.
Poon, Steve F., Brian Eastman, Deborah F. Chapman, et al.. (2004). 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 14(22). 5477–5480. 19 indexed citations
13.
Stearns, Brian A., Brian T. Campbell, Chixu Chen, et al.. (2004). Synthesis and biological evaluation of 6-aryl-6 H -pyrrolo[3,4- d ]pyridazine derivatives: high-affinity ligands to the α 2 δ subunit of voltage gated calcium channels. Bioorganic & Medicinal Chemistry Letters. 14(5). 1295–1298. 14 indexed citations
14.
Huang, Dehua, Steve F. Poon, Deborah F. Chapman, et al.. (2004). 2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 14(22). 5473–5476. 25 indexed citations
15.
Roppe, Jeffrey, Bowei Wang, Dehua Huang, et al.. (2004). 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorganic & Medicinal Chemistry Letters. 14(15). 3993–3996. 41 indexed citations
16.
Smith, Nicholas D., Steve F. Poon, Dehua Huang, et al.. (2004). Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorganic & Medicinal Chemistry Letters. 14(22). 5481–5484. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dong-Mei Feng Breakdown of academic impact, for papers by Erica O’Bryan Breakdown of academic impact, for papers by Itsuro Shimada Breakdown of academic impact, for papers by Jack A. Kauffman Breakdown of academic impact, for papers by Agustin O. Pineda Breakdown of academic impact, for papers by Christine Lambert‐van der Brempt Breakdown of academic impact, for papers by Gerard Costello Breakdown of academic impact, for papers by Rohan Mendonca Breakdown of academic impact, for papers by Christophe Thurieau Breakdown of academic impact, for papers by Da-Sheng Wang
Rankless by CCL
2026